Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 283

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 283
---
 of directors and is the managing member of Palkon GP, LLC. Dr. Wirk may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership of all shares held by the Palkon entities except to any pecuniary interest therein. (5) Consisted of 31,252 shares of Series B Preferred Stock held by Dr. Wirk. Dr. Wirk was a member of Legacy Tvardi’s board of directors. (6) Consisted of 173,448 shares of Series B Preferred Stock held by BioMatrix Partners Ltd. Wallace Hall was a member of Legacy Tvardi’s board of directors and a limited partner of BioMatrix Partners Ltd. As a limited partner of BioMatrix Partners Ltd., Mr. Hall has a pecuniary interest in any transactions involving the shares held by BioMatrix Partners. Founder Royalty Payments Pursuant to founder restricted stock purchase agreements, entered into on January 25, 2018, as amended, between Legacy Tvardi and each of its founders, David J. Tweardy, M.D., and Ron DePinho, M.D., we are obligated to pay royalties to each such founder in an amount equal to 1% each on the worldwide net sales of TTI-101 and any derivative formulations (“Royalty Bearing Product”). These royalty obligations last, on a country-by-country basis, for the later of (i) the date on which the sale of Royalty Bearing Product is no longer covered by a Covered Patent (as defined below) in such country, or 15 years after the first commercial sale of Royalty Bearing Product in such country. The timing of when its royalty payments will actually be made is uncertain as the payments are contingent upon future activities, including the successful development, regulatory approval and commercialization of a Royalty Bearing Product. A Covered Patent means, subject to certain customary exceptions, an issued patent that is owned by Legacy Tvardi or an affiliate, or for which all rights to develop and commercialize pharmaceutical products for the treatment of any human disorder, are exclusively licensed to Legacy Tvardi or an affiliate by the owner of such patent,

173

TABLE OF CONTENTS

with its right or its affiliate’s right to grant sublicenses. Each of Drs. Tweardy and DePinho beneficially own greater than 5% of our common stock. See “ Principal Securityholders” for more information.

#### Investor Agreements
In connection with Legacy T